Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study

Table 5 Adverse events after administration of one-shot CDDP via HAI and RT up to the time of the second response evaluation (median 4.3 month), as categorized by NCI-CTCAE v5.0

	All (N = 32)
Adverse event	Any grade	Grade ≥ 3
Fever	25 (8)	0
Aspartate aminotransferase increased	16 (5)	0
Alanine aminotransferase increased	12 (4)	0
Anorexia	6 (2)	0
Elevated ammonia	6 (2)	0
Ascites	3 (1)	0
Fatigue	3 (1)	0

The adverse events after administration of one-shot CDDP via HAI and RT up to time of the the second response evaluation (median 4.3 month), as categorized by NCI-CTCAE v5.0. Data are presented as percentages (numbers). CDDP cisplatin; HAI hepatic arterial infusion; RT radiation therapy; NCI-CTCAE National Cancer Institute Common Terminology Criteria for Adverse Event

ISSN: 1471-230X